Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan plus amoxicillin dual therapy versus bismuth quadruple therapy for first-line Helicobacter pylori eradication
ChiCTR2100048163Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vonoprazan, amoxicillin, esomeprazole, bismuth subsalicylate and clarithromycin in Helicobacter pylori infection (3 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Eradication rate. Planned start May 2021; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillinesomeprazolebismuth subsalicylateclarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2100048163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048163.